Allergy specialist ALK Abello (ALKB:DC) has announced that reimbursement has been agreed for its sublingual allergy immunotherapy tablet against Japanese cedar allergy, branded Cedarcure, in Japan.
The Danish company’s partner for the Asian country, Torii Pharmaceutical, has agreed a price with authorities and secured a listing on Japan’s National Health Insurance reimbursement list.
This clears the way for the launch of Cedarcure in the coming months in what is the second largest market for allergy medicines after the USA. ALK will be entitled to royalties from Japanese sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze